Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: RealMuLan who wrote (9144)	6/4/1998 3:41:00 PM
From: DaiS	Read Replies (2) \| Respond to of 23519

Yiwu, WHAT IS THIS PLEASE??!!??!!???!! I was lead on by the longs on this thread to believe that the covering shorts would drive the price up to 10,15,20 Explain please, DaiS PS Sorry didn't mean to shout

To: RealMuLan who wrote (9144)	6/4/1998 5:26:00 PM
From: VLAD	Read Replies (2) \| Respond to of 23519

Yiwu, Institutional shorts that know the business do not typically cover until they see a change in the trend. The shorts are smart and know that emotion not logic runs this market. The fear and panic selling is over now. Bargain hunters and short covering should take us back up to the 7 to 8 range in a day or two. Any good news can easily get us back to our old basing pattern of 10. At 6 5/16 we now have a market cap of 200 million with 1997 gross sales of 130 million. At this point I hope that a buyout occurs. Any big pharmaceutical company would pay 4 to 5 times sales revenue. This would give a price of at least $17.00 a share. The research and development costs on MUSE were probably in the neighborhood of $10.00/share. The patented delivery system alone is probably worth $10.00/share. A large pharmaceutical with an excellent research team can certainly develop improved drugs much faster than Vivus. Currently Vivus is worth 6 5/16 due to the perception that Viagra will destroy MUSE sales and the effect of massive shorting. On the contrary, with current liabilities of Viagra, most careful MD's will not even offer Viagra to any patient with cardiovascular disease. Add Viagra failures along with the increased awareness that Pfizer brings and then ask yourself if Vivus is no longer going to be a player in the ED market. If you think not then sell your stocks. If you think so then buy at these levels or hold on to your shares.